Mesa Laboratories (MLAB)
(Delayed Data from NSDQ)
$116.04 USD
-1.07 (-0.91%)
Updated May 10, 2024 04:00 PM ET
After-Market: $115.79 -0.25 (-0.22%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth C Momentum D VGM
Balance Sheet
Fiscal Year End for Mesa Laboratories, Inc falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 33 | 49 | 264 | 81 |
Receivables | NA | 43 | 41 | 24 | 21 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 35 | 25 | 11 | 14 |
Other Current Assets | NA | 9 | 9 | 5 | 6 |
Total Current Assets | NA | 119 | 124 | 304 | 123 |
Net Property & Equipment | NA | 28 | 29 | 22 | 22 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 1 | 1 | 1 | 11 |
Intangibles | NA | 503 | 541 | 273 | 261 |
Deposits & Other Assets | NA | 10 | 12 | 3 | 2 |
Total Assets | NA | 662 | 707 | 601 | 420 |
Liabilities & Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 6 | 8 | 4 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 23 | 26 | 18 | 15 |
Income Taxes Payable | NA | 0 | 0 | 2 | 0 |
Other Current Liabilities | NA | 14 | 14 | 9 | 7 |
Total Current Liabilities | NA | 43 | 48 | 33 | 26 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 34 | 39 | 16 | 33 |
Convertible Debt | NA | 170 | 169 | 146 | 140 |
Long-Term Debt | NA | 13 | 49 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 8 | 8 | 1 | 1 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 268 | 314 | 195 | 200 |
Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 332 | 313 | 318 | 158 |
Capital Surplus | NA | 0 | 0 | 0 | 0 |
Retained Earnings | NA | 74 | 77 | 72 | 72 |
Other Equity | NA | -13 | 4 | 16 | -10 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 393 | 394 | 406 | 220 |
Total Liabilities & Shareholder's Equity | NA | 662 | 707 | 601 | 420 |
Total Common Equity | 0 | 393 | 394 | 406 | 220 |
Shares Outstanding | 5.30 | 5.30 | 5.20 | 5.10 | 4.30 |
Book Value Per Share | 0.00 | 74.24 | 75.73 | 79.65 | 51.17 |
Fiscal Year End for Mesa Laboratories, Inc falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 28 | 36 | 32 | 33 |
Receivables | NA | 36 | 36 | 36 | 43 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 36 | 33 | 36 | 35 |
Other Current Assets | NA | 18 | 13 | 11 | 9 |
Total Current Assets | NA | 118 | 118 | 115 | 119 |
Net Property & Equipment | NA | 32 | 29 | 28 | 28 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 1 | 1 | 1 | 1 |
Intangibles | NA | 579 | 481 | 489 | 503 |
Deposits & Other Assets | NA | 12 | 9 | 10 | 10 |
Total Assets | NA | 742 | 637 | 643 | 662 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 5 | 5 | 6 | 6 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 25 | 21 | 18 | 23 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 14 | 14 | 15 | 14 |
Total Current Liabilities | NA | 44 | 40 | 39 | 43 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 44 | 33 | 34 | 34 |
Convertible Debt | NA | 171 | 171 | 171 | 170 |
Long-Term Debt | NA | 62 | 0 | 5 | 13 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 5 | 7 | 8 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 339 | 249 | 255 | 268 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 341 | 338 | 334 | 332 |
Capital Surplus | NA | 0 | 0 | 0 | 0 |
Retained Earnings | NA | 72 | 71 | 73 | 74 |
Other Equity | NA | -10 | -21 | -19 | -13 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 403 | 388 | 388 | 393 |
Total Liabilities & Shareholder's Equity | NA | 742 | 637 | 643 | 662 |
Total Common Equity | 0 | 403 | 388 | 388 | 393 |
Shares Outstanding | 5.30 | 5.30 | 5.30 | 5.30 | 5.30 |
Book Value Per Share | 0.00 | 76.03 | 73.16 | 73.15 | 74.24 |